NEWS & MEDIA
We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.
PRESS RELEASES
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board...
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination reduces the odds of having febrile neutropenia by 41% vs....
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer SymposiumNEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global...
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical...
BeyondSpring Announces Pricing of Ordinary Shares
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the pricing of its public offering of...
MEDIA
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.